Comparison of adverse event profiles of carfilzomib-, elotuzumab-, and ixazomib-based therapies combined with lenalidomide and dexamethasone in patients with multiple myeloma using VigiBase. - Matsumoto J; Takeda T; Sugimoto S; Sakai T; Loyao BB; Higashionna T; Hamano H; See GLL; Ariyoshi N; Zamami Y (Leukemia research, 2026)